Is a method of diagnostic nuclear medicine requested in order to locating or confirming the presence of neuroendocrine diseases. In addition to providing a whole body survey so as to detect if the tumor has metastasized to other areas, or simply to assess the response after a treatment. The tracer MIBG (Iodine-131-meta-iodobenzylguandine) is injected to explicitly gather in nerve tissues most commonly in pheochromocytoma and neuroblastoma. Fasting: Is not preferred as you will be requested to considerably increase fluid intake, consequently increasing urination frequency, as you will be requested to empty your bladder immediately prior to the procedure. Medication contradiction: A list of medications should be provided as they may interfere with the examination. The following medications should be stopped at least 5 days prior to the exam: Tricyclic antidepressants Antihypertensive drugs Sympathomimetics Decongestants containing pseudoephedrine, phenylpropanolamine and phenylephrine Tracer administration: The radiopharmaceutical tracer will be injected intravenously. Examination duration: The imaging process will take up from 30-60 minutes. Imaging will be conducted 24 hours after the injection and again 48 and 72 hours later. Other requirements: Upon instruction, you will be taking Lugol’s solution before and after the testing. Additional related examinations: Additional imaging maybe required depending on the examination outcome.